2017, new articles

Targeting iron metabolism in drug discovery and delivery.

Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.

A Red Carpet for Iron Metabolism.

Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt.

December, 2016

ASH meeting; see our papers in the event section

November, 2016

Article: Lack of Hepcidin Ameliorates Anemia and Improves Growth in an Adenine-induced Mouse Model of Chronic Kidney Disease.

Growth delay is common in children with chronic kidney disease (CKD), often associated with poor quality of life. Our study suggests that hepcidin appears to be related to pathways of growth retardation in CKD and that investigation of hepcidin lowering therapies in juvenile CKD is warranted.

August, 2016

Article: Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers.

A new powerful tool generated by the Blobel lab (see articles Deng W et al, Cell 2012 and Deng W et al, Cell 2014) is able to increase fetal hemoglobin in cells from sickle cell anemia patient in vitro.

July, 2016
Drug-like peptides show promise in treating 2 blood diseases

Our research suggests that synthetic peptides called minihepcidins may potentially treat two serious genetic blood diseases in children and adults. Although those diseases, beta-thalassemia and polycythemia vera, have opposite effects on red blood cell production, treating animals with minihepcidin helps to restore normal levels of red blood cells and reduces spleen enlargement.

Article: Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.

January, 2016

Article: Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.

Our study shows that an antisense oligonucleotide targeting Tmprss6 combined with the oral iron chelator DFP, is more powerful in reducing hepatic iron stores than either therapy alone, independently from dietary iron content.

November, 2015

Sultan bin Khalifa International Thalassemia Award - Innovative Medical Research award to Dr. Stefano Rivella